Radius Health Inc. (RDUS) Trading 2% Higher
Radius Health Inc. (NASDAQ:RDUS) traded up 2% during trading on Friday . The stock traded as high as $57.91 and last traded at $57.55, with a volume of 1,497,564 shares. The stock had previously closed at $56.40.
Several research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Monday, May 2nd. Canaccord Genuity reiterated a “buy” rating on shares of Radius Health in a research note on Tuesday, May 31st. Cowen and Company assumed coverage on shares of Radius Health in a research note on Friday, May 6th. They issued an “outperform” rating on the stock. Jefferies Group reiterated a “hold” rating on shares of Radius Health in a research note on Friday, August 5th. Finally, HC Wainwright assumed coverage on shares of Radius Health in a research note on Monday, May 23rd. They issued a “buy” rating and a $55.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Radius Health has a consensus rating of “Buy” and a consensus target price of $61.73.
The firm’s 50-day moving average is $46.90 and its 200-day moving average is $36.99. The company’s market capitalization is $2.44 billion.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by $0.06. During the same period in the prior year, the firm earned ($0.61) EPS. Equities analysts anticipate that Radius Health Inc. will post ($3.95) EPS for the current fiscal year.
A number of hedge funds and institutional investors have bought and sold shares of the stock. Dimensional Fund Advisors LP acquired a new position in Radius Health during the fourth quarter worth approximately $1,362,000. Wells Fargo & Company MN increased its position in Radius Health by 7.5% in the fourth quarter. Wells Fargo & Company MN now owns 422,217 shares of the biopharmaceutical company’s stock worth $25,984,000 after buying an additional 29,601 shares during the period. Finally, New York State Common Retirement Fund increased its position in Radius Health by 36.0% in the fourth quarter. New York State Common Retirement Fund now owns 69,048 shares of the biopharmaceutical company’s stock worth $4,249,000 after buying an additional 18,259 shares during the period.
Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.